

# ForPatients

*by Roche*

Juvenile Idiopathic Arthritis

## A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

**Trial Status**  
Completed

**Trial Runs In**  
12 Countries

**Trial Identifier**  
NCT01904279 2012-003486-18  
WA28117

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This open-label, multicenter study evaluated the pharmacokinetics, pharmacodynamics and safety of SC administered TCZ in participants with pJIA.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT01904279 2012-003486-18 WA28117**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=1 Year & <= 17 Years

**Healthy Volunteers**  
No

---